United States· US:25682-019_404d99e5-991e-4353-bb9f-29dfa00a43b3

STRENSIQ

A asfotase alfa product containing asfotase alfa, registered in United States by Alexion Pharmaceuticals, Inc.. The same ATC class is registered in 13 of our 19 countries.

ATC A16AB13US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedSTRENSIQATCA16AB13REGISTER NO.US:25682-019_404d99e5…PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Asfotase alfa is registered in 13 of 19 countries.

Countries holding a registration under ATC A16AB13 (asfotase alfa), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 9 of them publish a price we can compare per daily dose

Asfotase alfa · ATC A16AB13

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of asfotase alfa costs, country by country.

Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Asfotase alfa · price per daily dose (21.4 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1328.81
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
ASFOTASE ALFA
Manufacturer
Alexion Pharmaceuticals, Inc.
Country
United States (US)
ATC code
A16AB13
ATC class
Asfotase alfa
Defined daily dose
21.4 mg, P
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 2

  • ndc11
    2568201912
    12 VIAL in 1 CARTON (25682-019-12) / .8 mL in 1 VIAL (25682-019-01)
  • ndc11
    25682-019-12

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Asfotase alfa in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All asfotase alfa products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Strensiq
  • Liechtenstein · Strensiq
  • Norway · Strensiq

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2b606601-2f39-49ba-ac1e-33891ebc0f6c
GET /v1/drugs/2b606601-2f39-49ba-ac1e-33891ebc0f6c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "SUBCUTANEOUS",
  "source": "ndc",
  "strength": "80",
  "substance": "ASFOTASE ALFA",
  "productndc": "25682-019",
  "dosage_form": "SOLUTION",
  "dea_schedule": null,
  "strength_unit": "mg/.8mL",
  "application_number": "BLA125513",
  "marketing_category": "BLA"
}

See everything about asfotase alfa.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.